May 2016

CRANBURY, N.J., May 26, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial …

Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property Read More »

CRANBURY, N.J., May 17, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2016.  Quarter Ended March 31, 2016 and Recent Highlights Bremelanotide development for …

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on May 17, 2016 Read More »

CRANBURY, N.J., May 12, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2016 operating results on Tuesday, May 17, 2016  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 17, …

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2016 Results Read More »